Literature DB >> 8779135

Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1.

M F Wildhagen1, J B Verheij, J G Verzijl, H B Hilderink, L Kooij, T Tijmstra, L P ten Kate, J Gerritsen, W Bakker, J D Habbema, F Habbema.   

Abstract

BACKGROUND: Research on the cost of care of patients with cystic fibrosis is scarce. The aim of this study was to estimate the costs using age-specific medical consumption from real patient data.
METHODS: The age-specific medical consumption of patients with cystic fibrosis in The Netherlands in 1991 was estimated from a survey of medical records and a patient questionnaire. A distinction was made between costs of hospital care, hospital and non-hospital medication, and home care. Costs per year were obtained by multiplying the yearly amount of care and the costs per unit.
RESULTS: On average the annual cost of a patient with cystic fibrosis in 1991 was 10,908 pounds (hospital care 42%, medication 37%, home care 20%). The cost of care of cystic fibrosis in The Netherlands, with approximately 1000 patients, is estimated at 10.9 million pounds per year, which is 0.07% of the total health care budget. The cost of care of a patient up to the age of 35 is estimated at 614,587 pounds. When year-to-year survival is taken into account and future costs are discounted to the year of birth with a yearly discount rate of 5%, the cost of care of a patient with cystic fibrosis is estimated at 164,365 pounds for 1991. This estimate will be used in a prospective evaluation of screening for cystic fibrosis carriers.
CONCLUSIONS: The cost of care of patients with cystic fibrosis estimated by age-specific medical consumption of real patients is higher than that estimated by non-age-specific medical consumption and/or expert opinions.

Entities:  

Mesh:

Year:  1996        PMID: 8779135      PMCID: PMC1090643          DOI: 10.1136/thx.51.3.298

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  6 in total

1.  Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population.

Authors:  G Ginsberg; H Blau; E Kerem; C Springer; B S Kerem; E Akstein; A Greenberg; A Kolumbos; D Abeliovich; E Gazit
Journal:  Health Econ       Date:  1994 Jan-Feb       Impact factor: 3.046

2.  How cost-effective is breast cancer screening in different EC countries?

Authors:  B M van Ineveld; G J van Oortmarssen; H J de Koning; R Boer; P J van der Maas
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

3.  Home intravenous antibiotic treatment of patients with cystic fibrosis.

Authors:  B Strandvik; L Hjelte; A S Malmborg; B Widén
Journal:  Acta Paediatr       Date:  1992-04       Impact factor: 2.299

4.  [Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibrosis; a multicenter study].

Authors:  W Bakker; A A Vinks; J W Mouton; P de Jonge; J G Verzijl; H G Heijerman
Journal:  Ned Tijdschr Geneeskd       Date:  1993-11-27

5.  Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease.

Authors:  M A Donati; G Guenette; H Auerbach
Journal:  J Pediatr       Date:  1987-07       Impact factor: 4.406

6.  A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients.

Authors:  M Robson; J Abbott; K Webb; M Dodd; J Walsworth-Bell
Journal:  Thorax       Date:  1992-09       Impact factor: 9.139

  6 in total
  13 in total

1.  Cost effectiveness of DNA diagnosis for four monogenic diseases.

Authors:  A A van der Riet; B A van Hout; F F Rutten
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Costs, effects, and savings of screening for cystic fibrosis gene carriers.

Authors:  M F Wildhagen; H B Hilderink; J G Verzijl; J B Verheij; L Kooij; T Tijmstra; L P ten Kate; J D Habbema
Journal:  J Epidemiol Community Health       Date:  1998-07       Impact factor: 3.710

4.  [Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment].

Authors:  J M Graf von der Schulenburg; W Greiner; U Klettke; U Wahn
Journal:  Med Klin (Munich)       Date:  1997-10-15

Review 5.  Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Authors:  K L Goa; H Lamb
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

6.  Hospitalisation costs of cystic fibrosis.

Authors:  Jonas Schreyögg; Helge Hollmeyer; Miriam Bluemel; Doris Staab; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.

Authors:  Mareike Heimeshoff; Helge Hollmeyer; Jonas Schreyögg; Oliver Tiemann; Doris Staab
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.981

Review 8.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  [Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results].

Authors:  Daniela Eidt; Thomas Mittendorf; Thomas O F Wagner; Andreas Reimann; J-Matthias Graf von der Schulenburg
Journal:  Med Klin (Munich)       Date:  2009-07-18

Review 10.  Exacerbations in cystic fibrosis: 2 . prevention.

Authors:  Scott C Bell; Philip J Robinson
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.